Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
ONCOLOGY (2017)
期刊
ONCOLOGY
卷 93, 期 -, 页码 147-159出版社
KARGER
关键词
类别
资金
- Grants-in-Aid for Scientific Research [15K09028] Funding Source: KAKEN
作者
我是这篇论文的作者
推荐
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
LANCET ONCOLOGY (2021)
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib
May Tun Saung, Lorraine Pelosof, Sandra Casak, Martha Donoghue, Steven Lemery, Mengdie Yuan, Lisa Rodriguez, Peter Schotland, Meredith Chuk, Gina Davis, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola Fashoyin-Aje
ONCOLOGIST (2021)
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Yen-Hao Chen, Ching-Hua Tsai, Yen-Yang Chen, Chih-Chi Wang, Jing-Houng Wang, Chao-Hung Hung, Yuan-Hung Kuo
BMC CANCER (2023)
Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates
Dmitrii Shek, Scott A. Read, Adnan Nagrial, Matteo S. Carlino, Bo Gao, Jacob George, Golo Ahlenstiel
ONCOLOGIST (2021)
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shukui Qin, David W-M Tai, Ho Yeong Lim, Thomas Yau, Wei-Peng Yong, Ann-Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh Borad, Johanna Bendell, Tae-You Kim, Nathan Standifer, Philip He, Mallory Makowsky, Alejandra Negro, Masatoshi Kudo, Ghassan K. Abou-Alfa
JOURNAL OF CLINICAL ONCOLOGY (2021)
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Alvaro Lopez-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
NATURE MEDICINE (2023)
Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?
Khalil Saleh, Manal Kordahi, Tony Felefly, Hampig Raphael Kourie, Nadine Khalife
FUTURE ONCOLOGY (2022)
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano
NATURE COMMUNICATIONS (2023)
Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
Espen B. Ellingsen, Steven O'Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S. Kristedja, Mohammed Milhem, Yousef Zakharia
CLINICAL CANCER RESEARCH (2023)
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
Georgina Long, Jason J. Luke, Muhammad A. Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S. Carlino, Peter Mohr, Reinhard Dummer, Jeffrey E. Gershenwald, Charles H. Yoon, Xi Lawrence Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. M. Eggermont, Paolo A. Ascierto
LANCET ONCOLOGY (2022)
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
Daniel Roessler, Osman Oecal, Alexander B. Philipp, Daniel Markwardt, Stefan Munker, Julia Mayerle, Leonie S. Jochheim, Katharina Hammer, Christian M. Lange, Andreas Geier, Max Seidensticker, Florian P. Reiter, Enrico N. De Toni, Najib Ben Khaled
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
Hsin-Yu Kuo, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, Chiao-Hsiung Chuang, I-Chin Wu, Juei-Seng Wu, Tzu-Chun Hong, Ming-Tsung Hsieh, Yang-Cheng Lee, Hung-Tsung Wu, Hong-Ming Tsai
PHARMACEUTICS (2022)
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
Priscilla K. K. Brastianos, Albert E. E. Kim, Anita Giobbie-Hurder, Eudocia Q. Q. Lee, Nancy U. U. Lin, Beth Overmoyer, Patrick Y. Y. Wen, Lakshmi Nayak, Justine V. V. Cohen, Jorg Dietrich, April Eichler, Rebecca S. S. Heist, Ian Krop, Donald Lawrence, Jennifer Ligibel, Sara Tolaney, Erica Mayer, Eric Winer, Brittany Bent, Magali A. A. de Sauvage, Nazanin Ijad, Juliana M. M. Larson, Braxton Marion, Sally Nason, Naina Murthy, Sherry Ratcliff, Elizabeth J. J. Summers, Maura Mahar, Helen A. A. Shih, Kevin Oh, Daniel P. P. Cahill, Elizabeth R. R. Gerstner, Ryan J. J. Sullivan
NATURE MEDICINE (2023)
Nivolumab plus Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Josephine Tsang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Bryan Cho Wing Li, Roland Leung, Joanne Chiu, Tan to Cheung, Thomas Yau
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
FUTURE ONCOLOGY (2022)
Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky
LIVER CANCER (2023)
Artificial intelligence models for the diagnosis and management of liver diseases
Naoshi Nishida, Masatoshi Kudo
ULTRASONOGRAPHY (2023)
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
EUROPEAN JOURNAL OF CANCER (2023)
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study
Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura
HEPATOLOGY RESEARCH (2023)
Treatment of portal hypertension in patients with HCC in the era of Baveno VII
Dominique Thabut, Masatoshi Kudo
JOURNAL OF HEPATOLOGY (2023)
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
ONCOLOGY (2023)
Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence
Yasunori Minami, Naoshi Nishida, Masatoshi Kudo
LIVER CANCER (2023)
Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review
Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
LIVER CANCER (2023)
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study
Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
LIVER CANCER (2023)
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
LIVER CANCER (2023)
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
LIVER CANCER (2023)
Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L. Chan, Masayuki Kurosaki, Namiki Izumi
LIVER CANCER (2023)
Advances in Immunotherapy for Hepatocellular Carcinoma
Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo
CANCERS (2023)
Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo
CASE REPORTS IN MEDICINE (2023)
Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015)
Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, Masayuki Kurosaki, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Nakashima Osamu, Takumi Fukumoto, Yutaka Matsuyama, Takamichi Murakami, Arata Takahashi, Hiroaki Miyata, Norihiro Kokudo
HEPATOLOGY RESEARCH (2023)